Nouri Neamati

This inventor holds 10 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: University of Southern California, University of Michigan, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2006-2022.

USPTO Granted Patents = 10 (Patent Applications = 15)

% Patents Active = 60.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 30(Granted Patents)

Location History:

Los Angeles, CA (US) (2012)
Fullerton, CA (US) (2006 - 2013)
Ann Arbor, MI (US) (2016 - 2022)

Company Filing History:

6 out of 1,691

University of Southern California

patents

3 out of 3,523

University of Michigan

patents

1 out of 3,690

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

4. 1 out of 5,630

The University of Texas System

patents

5. 1 out of 3

Università Degli Studi Di Sassari

where one patent can have more than one assignee

Years Active: 2006-2022

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11214567 - Small molecule inhibitors of MYC and uses thereof (2022-01-04),

2. 10781183 - Small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity (2020-09-22),

3. 10457662 - Substituted amides for treating and preventing cancer (2019-10-29),

4. 10246446 - Blockers of the growth hormone receptor in disease prevention and treatment (2019-04-02),

5. 9234018 - Compositions and methods for the treatment of VprBP-related cancers (2016-01-12),

6. 8445677 - Substituted pyrimidyl guanidine derivatives having anticancer activity (2013-05-21),

7. 8183236 - Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics (2012-05-22),

8. 7947682 - Substituted N'-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents (2011-05-24),

9. 7928113 - Integrin-binding small molecules (2011-04-19),

10. 7015212 - Thiazepine inhibitors of HIV-1 integrase (2006-03-21),

Title: Nouri Neamati: Innovator in Medicinal Chemistry

Introduction

Nouri Neamati is a prominent inventor based in Ann Arbor, MI (US), known for his significant contributions to the field of medicinal chemistry. With a total of 10 patents to his name, he has made remarkable strides in developing innovative therapeutic solutions for cancer and other diseases.

Latest Patents

One of Neamati's latest patents is focused on small molecule inhibitors of MYC and their uses. This invention introduces a new class of small molecules characterized by an oxadiazole-oxadiazolone structure. These compounds, including oxadiazole-phenyl-oxadiazolone, oxadiazole-pyridine-oxadiazolone, and others, are designed to serve as therapeutics for cancer treatment. Another notable patent involves small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity. This invention features a quinazolinedione structure that functions as ROS inducers and mitochondrial activity inhibitors within cancer cells, particularly targeting pancreatic cancer.

Career Highlights

Throughout his career, Neamati has worked with esteemed institutions such as the University of Southern California and the University of Michigan. His work has been instrumental in advancing the understanding and treatment of various diseases through innovative medicinal chemistry.

Collaborations

Neamati has collaborated with notable colleagues, including Raveendra S Dayam and Antonio Garofalo, contributing to the development of groundbreaking therapeutic solutions.

Conclusion

Nouri Neamati's work in medicinal chemistry exemplifies the impact of innovative thinking in addressing critical health challenges. His patents and collaborations highlight his commitment to advancing cancer treatment and improving patient outcomes.